These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 38286304)
1. Is schedule IV suvorexant an appropriate reference drug of abuse to use in preclinical abuse liability testing in the rat? Teuns GBA; Tessari M Regul Toxicol Pharmacol; 2024 Mar; 148():105570. PubMed ID: 38286304 [TBL] [Abstract][Full Text] [Related]
2. Failure of the dual orexin receptor antagonist suvorexant to engender drug discrimination in rats. Steiner MA; Toeroek-Schafroth M; Dacome L; Tessari M J Psychopharmacol; 2023 Dec; 37(12):1261-1264. PubMed ID: 37982383 [TBL] [Abstract][Full Text] [Related]
3. Preclinical assessment of the abuse potential of the orexin receptor antagonist, suvorexant. Born S; Gauvin DV; Mukherjee S; Briscoe R Regul Toxicol Pharmacol; 2017 Jun; 86():181-192. PubMed ID: 28279667 [TBL] [Abstract][Full Text] [Related]
4. Assessment of the Abuse Potential of the Orexin Receptor Antagonist, Suvorexant, Compared With Zolpidem in a Randomized Crossover Study. Schoedel KA; Sun H; Sellers EM; Faulknor J; Levy-Cooperman N; Li X; Kennedy WP; Cha JH; Lewis NM; Liu W; Bondiskey P; McCrea JB; Panebianco DL; Troyer MD; Wagner JA J Clin Psychopharmacol; 2016 Aug; 36(4):314-23. PubMed ID: 27253658 [TBL] [Abstract][Full Text] [Related]
5. Abuse potential assessment of the new dual orexin receptor antagonist daridorexant in recreational sedative drug users as compared to suvorexant and zolpidem. Ufer M; Kelsh D; Schoedel KA; Dingemanse J Sleep; 2022 Mar; 45(3):. PubMed ID: 34480579 [TBL] [Abstract][Full Text] [Related]
6. Suvorexant, an orexin/hypocretin receptor antagonist, attenuates motivational and hedonic properties of cocaine. Gentile TA; Simmons SJ; Barker DJ; Shaw JK; España RA; Muschamp JW Addict Biol; 2018 Jan; 23(1):247-255. PubMed ID: 28419646 [TBL] [Abstract][Full Text] [Related]
7. Can the Orexin Antagonist Suvorexant Preserve the Ability to Awaken to Auditory Stimuli While Improving Sleep? Drake CL; Kalmbach DA; Cheng P; Roth T; Tran KM; Cuamatzi-Castelan A; Atkinson R; Singh M; Tonnu CV; Fellman-Couture C J Clin Sleep Med; 2019 Sep; 15(9):1285-1291. PubMed ID: 31538599 [TBL] [Abstract][Full Text] [Related]
8. Effects of the orexin receptor antagonist suvorexant on respiration during sleep in healthy subjects. Uemura N; McCrea J; Sun H; Donikyan M; Zammit G; Liu R; Louridas B; Marsilio S; Lines C; Troyer MD; Wagner J J Clin Pharmacol; 2015 Oct; 55(10):1093-100. PubMed ID: 25903940 [TBL] [Abstract][Full Text] [Related]
9. Suvorexant maintenance enhances the reinforcing but not subjective and physiological effects of intravenous cocaine in humans. Stoops WW; Strickland JC; Hatton KW; Hays LR; Rayapati AO; Lile JA; Rush CR Pharmacol Biochem Behav; 2022 Oct; 220():173466. PubMed ID: 36152876 [TBL] [Abstract][Full Text] [Related]
10. Role of hypocretin/orexin receptor blockade on drug-taking and ultrasonic vocalizations (USVs) associated with low-effort self-administration of cathinone-derived 3,4-methylenedioxypyrovalerone (MDPV) in rats. Simmons SJ; Martorana R; Philogene-Khalid H; Tran FH; Gentile TA; Xu X; Su S; Rawls SM; Muschamp JW Psychopharmacology (Berl); 2017 Nov; 234(21):3207-3215. PubMed ID: 28786030 [TBL] [Abstract][Full Text] [Related]
11. Suvorexant: a dual orexin receptor antagonist for the treatment of sleep onset and sleep maintenance insomnia. Patel KV; Aspesi AV; Evoy KE Ann Pharmacother; 2015 Apr; 49(4):477-83. PubMed ID: 25667197 [TBL] [Abstract][Full Text] [Related]